Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O’neill Sells 5,394 Shares

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Gilmore Neil O’neill sold 5,394 shares of Editas Medicine stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $2.02, for a total transaction of $10,895.88. Following the completion of the transaction, the chief executive officer owned 263,693 shares of the company’s stock, valued at $532,659.86. The trade was a 2.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Editas Medicine Stock Performance

EDIT stock traded up $0.15 during midday trading on Wednesday, reaching $2.19. 2,113,012 shares of the company’s stock traded hands, compared to its average volume of 1,750,009. Editas Medicine, Inc. has a 52 week low of $0.91 and a 52 week high of $4.54. The firm has a market capitalization of $213.79 million, a PE ratio of -0.92 and a beta of 2.16. The company has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $2.59.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Sei Investments Co. bought a new stake in shares of Editas Medicine in the 3rd quarter worth $46,000. Victory Capital Management Inc. bought a new position in shares of Editas Medicine during the third quarter valued at $36,000. StoneX Group Inc. purchased a new stake in shares of Editas Medicine during the fourth quarter valued at $33,000. Captrust Financial Advisors purchased a new stake in shares of Editas Medicine during the second quarter valued at $26,000. Finally, Eversept Partners LP bought a new stake in Editas Medicine in the 4th quarter worth about $596,000. 71.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Chardan Capital upgraded shares of Editas Medicine from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.00.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.